Cordis Trufill Embolic System Approval Is Fledgling Neurovascular Unit's First
This article was originally published in The Gray Sheet
Executive Summary
Cordis Neurovascular plans to launch the Trufill n-butyl cyanoacrylate (n-BCA) liquid embolic system for treatment of cerebral arteriovenous malformations (AVMs) the week of Oct. 2 following FDA approval of the neurovascular glue Sept. 26.
You may also be interested in...
MTI Aims To Rebound From Onyx Trial Delays, Focuses European Business
Micro Therapeutics, Inc.'s pivotal study of its Onyx liquid embolic system for the treatment of brain aneurysms will remain on target for completion by the third quarter of 2002, with 138 patients on board as predicted, the firm says
MTI Aims To Rebound From Onyx Trial Delays, Focuses European Business
Micro Therapeutics, Inc.'s pivotal study of its Onyx liquid embolic system for the treatment of brain aneurysms will remain on target for completion by the third quarter of 2002, with 138 patients on board as predicted, the firm says
J&J/Cordis Trufill Embolic Agent PMA Gains Panel Okay For Brain AVMs
Approval of Cordis' Trufill liquid embolic agent should be conditioned on the company's completion of studies requested by FDA in an earlier deficiency letter on the firm's premarket approval application, the agency's Neurological Devices Advisory Panel agreed at its May 11 meeting in Gaithersburg, Maryland.